Nisha Durand

649 total citations
24 papers, 488 citations indexed

About

Nisha Durand is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Nisha Durand has authored 24 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 8 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Nisha Durand's work include Mesenchymal stem cell research (9 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and Biomedical Ethics and Regulation (2 papers). Nisha Durand is often cited by papers focused on Mesenchymal stem cell research (9 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and Biomedical Ethics and Regulation (2 papers). Nisha Durand collaborates with scholars based in United States, Germany and Singapore. Nisha Durand's co-authors include Peter Störz, Abba C. Zubair, Sahra Borgés, Sarah Macklin, Paldeep S. Atwal, Stephanie L. Hines, Jorge M. Mallea, Loren E. Glover, Ligia I. Bastea and Heike Döppler and has published in prestigious journals such as Scientific Reports, Biochemical Journal and Cellular and Molecular Life Sciences.

In The Last Decade

Nisha Durand

24 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nisha Durand United States 11 208 126 102 79 74 24 488
Bettina Baron‐Lühr Germany 6 293 1.4× 145 1.2× 90 0.9× 34 0.4× 81 1.1× 6 649
Patrycja Pawlikowska France 15 391 1.9× 70 0.6× 177 1.7× 54 0.7× 137 1.9× 24 682
Claudia Cappuzzello Italy 12 263 1.3× 63 0.5× 124 1.2× 69 0.9× 127 1.7× 19 538
Saiphone Webb United States 12 444 2.1× 67 0.5× 90 0.9× 60 0.8× 66 0.9× 16 703
Monika Lejman Poland 15 282 1.4× 67 0.5× 164 1.6× 69 0.9× 92 1.2× 98 734
Fábio Motta Italy 12 288 1.4× 110 0.9× 93 0.9× 33 0.4× 68 0.9× 28 511
Randall Grose Australia 15 140 0.7× 54 0.4× 64 0.6× 66 0.8× 23 0.3× 25 510
Emily M. King United States 11 356 1.7× 41 0.3× 94 0.9× 73 0.9× 29 0.4× 16 589
Philip E. Boulais United States 9 230 1.1× 158 1.3× 185 1.8× 21 0.3× 45 0.6× 15 643
Mary A. Bewick Canada 13 225 1.1× 45 0.4× 157 1.5× 39 0.5× 80 1.1× 16 451

Countries citing papers authored by Nisha Durand

Since Specialization
Citations

This map shows the geographic impact of Nisha Durand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nisha Durand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nisha Durand more than expected).

Fields of papers citing papers by Nisha Durand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nisha Durand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nisha Durand. The network helps show where Nisha Durand may publish in the future.

Co-authorship network of co-authors of Nisha Durand

This figure shows the co-authorship network connecting the top 25 collaborators of Nisha Durand. A scholar is included among the top collaborators of Nisha Durand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nisha Durand. Nisha Durand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qu, Wenchun, Dan Yan, Nisha Durand, et al.. (2025). Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial. Stem Cell Research & Therapy. 16(1). 596–596. 1 indexed citations
2.
Song, Hannah, Amanda A. Mack, Nisha Durand, et al.. (2024). Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group. Cytotherapy. 26(11). 1275–1284. 3 indexed citations
3.
Yan, Dan, Abba C. Zubair, Jeffrey A. Stone, et al.. (2024). CellKine clinical trial: first report from a phase 1 trial of allogeneic bone marrow–derived mesenchymal stem cells in subjects with painful lumbar facet joint arthropathy. PAIN Reports. 9(5). e1181–e1181. 2 indexed citations
4.
Durand, Nisha, Lindsay C. Davies, Dominic Clarke, et al.. (2024). Particulates in CGT guidance survey results – an ISCT process development & manufacturing committee perspective on cell and gene therapy industry knowledge awareness. Cytotherapy. 27(3). 287–294. 1 indexed citations
5.
Durand, Nisha, Hyun‐Goo Kim, Vishal Patel, et al.. (2023). Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial. Neurocritical Care. 41(1). 59–69. 3 indexed citations
6.
7.
Molina, Samuel A., Steve Oh, Nisha Durand, et al.. (2022). Particulates are everywhere, but are they harmful in cell and gene therapies?. Cytotherapy. 24(12). 1195–1200. 4 indexed citations
8.
Ylöstalo, Joni & Nisha Durand. (2022). Enhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes. Directory of Open access Books (OAPEN Foundation). 1 indexed citations
9.
Durand, Nisha & Abba C. Zubair. (2021). Autologous versus allogeneic mesenchymal stem cell therapy: The pros and cons. Surgery. 171(5). 1440–1442. 9 indexed citations
10.
Huang, Peng, Nisha Durand, Cuiping Zhang, et al.. (2020). Feasibility, potency, and safety of growing human mesenchymal stem cells in space for clinical application. npj Microgravity. 6(1). 16–16. 43 indexed citations
11.
Durand, Nisha, Jorge M. Mallea, & Abba C. Zubair. (2020). Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. npj Regenerative Medicine. 5(1). 17–17. 39 indexed citations
12.
Durand, Nisha, et al.. (2020). CXCR4-overexpressing Mesenchymal Stem Cells exhibit increased cell migration and cytokine secretion. Cytotherapy. 22(5). S80–S80. 1 indexed citations
13.
Durand, Nisha, et al.. (2019). Effect of Comedications and Endotoxins on Mesenchymal Stem Cell Secretomes, Migratory and Immunomodulatory Capacity. Journal of Clinical Medicine. 8(4). 497–497. 18 indexed citations
14.
Macklin, Sarah, Nisha Durand, Paldeep S. Atwal, & Stephanie L. Hines. (2017). Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. Genetics in Medicine. 20(3). 346–350. 83 indexed citations
15.
Durand, Nisha, Ligia I. Bastea, Heike Döppler, Tim Eiseler, & Peter Störz. (2017). Src-mediated tyrosine phosphorylation of Protein Kinase D2 at focal adhesions regulates cell adhesion. Scientific Reports. 7(1). 9524–9524. 8 indexed citations
16.
Durand, Nisha, et al.. (2016). Protein Kinase D1 regulates focal adhesion dynamics and cell adhesion through Phosphatidylinositol-4-phosphate 5-kinase type-l γ. Scientific Reports. 6(1). 35963–35963. 10 indexed citations
17.
Durand, Nisha & Peter Störz. (2016). Targeting reactive oxygen species in development and progression of pancreatic cancer. Expert Review of Anticancer Therapy. 17(1). 19–31. 60 indexed citations
18.
Durand, Nisha, Sahra Borgés, & Peter Störz. (2015). Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. Cellular and Molecular Life Sciences. 72(22). 4369–4382. 25 indexed citations
19.
Lewis‐Tuffin, Laura J., Ryan W. Feathers, Priya Hari, et al.. (2015). Src family kinases differentially influence glioma growth and motility. Molecular Oncology. 9(9). 1783–1798. 51 indexed citations
20.
Bastea, Ligia I., et al.. (2013). Protein kinase D-mediated phosphorylation at Ser99 regulates localization of p21-activated kinase 4. Biochemical Journal. 455(2). 251–260. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bettina Baron‐Lühr Breakdown of academic impact, for papers by Patrycja Pawlikowska Breakdown of academic impact, for papers by Claudia Cappuzzello Breakdown of academic impact, for papers by Saiphone Webb Breakdown of academic impact, for papers by Monika Lejman Breakdown of academic impact, for papers by Fábio Motta Breakdown of academic impact, for papers by Randall Grose Breakdown of academic impact, for papers by Emily M. King Breakdown of academic impact, for papers by Philip E. Boulais Breakdown of academic impact, for papers by Mary A. Bewick
Rankless by CCL
2026